• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

ESR2 多态性与前列腺癌风险:系统评价和荟萃分析。

ESR2 polymorphisms on prostate cancer risk: A systematic review and meta-analysis.

机构信息

Department of Urology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.

出版信息

Medicine (Baltimore). 2023 Jun 9;102(23):e33937. doi: 10.1097/MD.0000000000033937.

DOI:10.1097/MD.0000000000033937
PMID:37335680
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10256358/
Abstract

BACKGROUND

This meta-analysis was performed to address the association of 2 ESR2 gene polymorphisms (rs1256049 and rs4986938) with susceptibility to cancer.

METHODS

An extensive literature search for eligible candidate gene studies published before May 10, 2022, was conducted in PubMed, Medline, and Web of Science. The search strategy was as follows: (ESR2 OR ERβ OR ER beta OR estrogen receptor beta) AND (polymorphism OR mutation OR variation OR SNP OR genotype) AND (PCa OR PC OR prostate cancer). Potential sources of heterogeneity were sought out via trial sequential analysis, subgroup, and sensitivity analysis.

RESULTS

Overall, a total of 10 articles involving 18,064 cases and 19,556 controls for 2 polymorphisms of the ESR2 gene were enrolled. In the stratified analysis of rs1256049, we found that Caucasians might be correlated with an increased risk of prostate cancer (PCa), while less susceptibility was found in Asians. We observed that rs4986938 was not associated with PCa risk.

CONCLUSION

ESR2 rs1256049 polymorphism is associated with a higher risk of PCa in the Caucasian population and a lower risk of PCa in the Asian population.

摘要

背景

本荟萃分析旨在探讨 2 个 ESR2 基因多态性(rs1256049 和 rs4986938)与癌症易感性的关联。

方法

在 PubMed、Medline 和 Web of Science 上进行了广泛的文献检索,以查找截至 2022 年 5 月 10 日发表的合格候选基因研究。搜索策略如下:(ESR2 或 ERβ 或 ER beta 或雌激素受体β)和(多态性或突变或变异或 SNP 或基因型)和(PCa 或 PC 或前列腺癌)。通过试验序贯分析、亚组和敏感性分析寻找潜在的异质性来源。

结果

总体而言,共纳入了 10 项研究,涉及 ESR2 基因的 2 个多态性,共纳入了 18064 例病例和 19556 例对照。在 rs1256049 的分层分析中,我们发现白种人可能与前列腺癌(PCa)的风险增加相关,而亚洲人则发现其相关性较低。我们观察到 rs4986938 与 PCa 风险无关。

结论

ESR2 rs1256049 多态性与白种人群中 PCa 的风险增加相关,与亚洲人群中 PCa 的风险降低相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46c2/10256358/87e129b1a907/medi-102-e33937-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46c2/10256358/5b81c8e02c74/medi-102-e33937-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46c2/10256358/f97ca84f6a84/medi-102-e33937-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46c2/10256358/d6e403e2fd50/medi-102-e33937-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46c2/10256358/87e129b1a907/medi-102-e33937-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46c2/10256358/5b81c8e02c74/medi-102-e33937-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46c2/10256358/f97ca84f6a84/medi-102-e33937-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46c2/10256358/d6e403e2fd50/medi-102-e33937-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46c2/10256358/87e129b1a907/medi-102-e33937-g004.jpg

相似文献

1
ESR2 polymorphisms on prostate cancer risk: A systematic review and meta-analysis.ESR2 多态性与前列腺癌风险:系统评价和荟萃分析。
Medicine (Baltimore). 2023 Jun 9;102(23):e33937. doi: 10.1097/MD.0000000000033937.
2
The influence of ESR1 rs9340799 and ESR2 rs1256049 polymorphisms on prostate cancer risk.ESR1基因rs9340799和ESR2基因rs1256049多态性对前列腺癌风险的影响。
Tumour Biol. 2014 Aug;35(8):8319-28. doi: 10.1007/s13277-014-2086-7. Epub 2014 May 24.
3
Association between the Estrogen receptor β rs1256049 polymorphism and prostate cancer risk:a meta-analysis.雌激素受体β rs1256049 多态性与前列腺癌风险的关联:一项荟萃分析。
Ann Biol Clin (Paris). 2023 Jul 21;81(3):280-288. doi: 10.1684/abc.2023.1815.
4
Association of estrogen receptor-beta (ESR2) polymorphism and cancer risk: a meta-analysis.雌激素受体-β(ESR2)基因多态性与癌症风险的关联:一项荟萃分析。
Eur J Gynaecol Oncol. 2016 Aug;37(4):530-538.
5
Associations between estrogen receptor genetic polymorphisms, smoking status, and prostate cancer risk: a case-control study in Japanese men.雌激素受体基因多态性、吸烟状况与前列腺癌风险之间的关联:一项针对日本男性的病例对照研究。
Environ Health Prev Med. 2015 Sep;20(5):332-7. doi: 10.1007/s12199-015-0471-5. Epub 2015 Aug 7.
6
A systematic review of the relationship between polymorphic sites in the estrogen receptor-beta (ESR2) gene and breast cancer risk.雌激素受体-β(ESR2)基因多态性位点与乳腺癌风险关系的系统评价。
Breast Cancer Res Treat. 2011 Feb;126(1):37-45. doi: 10.1007/s10549-010-0891-2.
7
Estrogen receptors alpha (rs2234693 and rs9340799), and beta (rs4986938 and rs1256049) genes polymorphism in prostate cancer: evidence for association with risk and histopathological tumor characteristics in Iranian men.雌激素受体 α(rs2234693 和 rs9340799)和 β(rs4986938 和 rs1256049)基因多态性与前列腺癌的关系:伊朗男性风险和组织病理学肿瘤特征的关联证据。
Mol Carcinog. 2012 Oct;51 Suppl 1:E104-17. doi: 10.1002/mc.21870. Epub 2012 Jan 6.
8
Estrogen receptor beta (ESR2) gene polymorphism and susceptibility to dementia.雌激素受体β(ESR2)基因多态性与痴呆易感性。
Acta Neurol Belg. 2021 Oct;121(5):1281-1293. doi: 10.1007/s13760-020-01360-z. Epub 2020 Apr 25.
9
CYP19 and ESR2 polymorphisms as potential culprits in cryptorchidism.细胞色素P450 19(CYP19)和雌激素受体2(ESR2)基因多态性作为隐睾症的潜在病因
J Pediatr Urol. 2025 Apr;21(2):497-503. doi: 10.1016/j.jpurol.2024.12.008. Epub 2024 Dec 14.
10
Estrogen receptor 2 gene polymorphism in idiopathic scoliosis.特发性脊柱侧凸中雌激素受体2基因多态性
Spine (Phila Pa 1976). 2014 Dec 15;39(26):E1599-607. doi: 10.1097/BRS.0000000000000643.

引用本文的文献

1
Gut microbiota, metabolites, and cytokines in relation to the risk of prostate cancer in the Asian population.亚洲人群中肠道微生物群、代谢产物和细胞因子与前列腺癌风险的关系。
Front Oncol. 2025 Jan 15;14:1466190. doi: 10.3389/fonc.2024.1466190. eCollection 2024.
2
Revealing the Antiperspirant Components of Floating Wheat and Their Mechanisms of Action through Metabolomics and Network Pharmacology.通过代谢组学和网络药理学揭示浮麦的止汗成分及其作用机制。
Molecules. 2024 Jan 23;29(3):553. doi: 10.3390/molecules29030553.

本文引用的文献

1
Liquid Biopsy in Prostate Cancer Management-Current Challenges and Future Perspectives.前列腺癌管理中的液体活检——当前挑战与未来展望
Cancers (Basel). 2022 Jul 4;14(13):3272. doi: 10.3390/cancers14133272.
2
BRCA Germline Mutations in Prostate Cancer: The Future Is Tailored.前列腺癌中的BRCA种系突变:未来是个性化的。
Diagnostics (Basel). 2021 May 19;11(5):908. doi: 10.3390/diagnostics11050908.
3
Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer.晚期前列腺癌治疗选择的诊断策略
Diagnostics (Basel). 2021 Feb 19;11(2):345. doi: 10.3390/diagnostics11020345.
4
Association between estrogen receptor β polymorphisms and prostate cancer in a Slovak population.斯洛伐克人群中雌激素受体β基因多态性与前列腺癌的关联。
Oncol Lett. 2021 Mar;21(3):214. doi: 10.3892/ol.2021.12475. Epub 2021 Jan 19.
5
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.EAU-EANM-ESTRO-ESUR-SIOG 前列腺癌指南-2020 版更新。第 1 部分:筛查、诊断和以治愈为目的的局部治疗。
Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7.
6
Expanding cancer predisposition genes with ultra-rare cancer-exclusive human variations.扩展具有超罕见癌症特有的人类变异的癌症易感性基因。
Sci Rep. 2020 Aug 10;10(1):13462. doi: 10.1038/s41598-020-70494-0.
7
No Association between Estrogen Receptor-Β Rs4986938 and Cancer Risk: A Systematic Review and Meta-Analysis.雌激素受体-β Rs4986938与癌症风险之间无关联:一项系统评价与Meta分析
Iran J Public Health. 2019 May;48(5):784-795.
8
Impact of Genetic Variants in Estrogen Receptor-β Gene in the Etiology of Uterine Leiomyomas.雌激素受体-β基因的遗传变异在子宫肌瘤病因学中的作用
J Reprod Infertil. 2019 Jul-Sep;20(3):151-160.
9
Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.前列腺癌种系变异的流行情况及其对当前遗传检测指南的影响。
JAMA Oncol. 2019 Apr 1;5(4):523-528. doi: 10.1001/jamaoncol.2018.6760.
10
Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.与雌激素代谢和功能相关的基因多态性与前列腺癌风险的关联:来自前列腺癌预防试验的结果。
Carcinogenesis. 2018 Feb 9;39(2):125-133. doi: 10.1093/carcin/bgx144.